Trial
NCT01003678
Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
Genzyme, a Sanofi Company
Condition
Myelodysplastic Syndrome
Intervention
Clofarabine
Why stopped
Drug provider withdrew support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-03